Basic information
Biomarker: MLH1
Histology type: endometrial carcinoma
Cohort characteristics
Country: Japan
Region: Tokorozawa
Study type: retrospective study
Followed up time :
Subgroup 1 name : retained
Subgroup 1 number: 138
Subgroup 2 name: loss
Subgroup 2 number: 53
Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
---|---|---|---|---|---|---|---|---|
191 | EC | 191 |
Sample information
Conclusion: MMR-related proteins expression was identified as an independent prognostic factor for OS, suggesting that MMR was a key biomarker for further investigations of endometrial cancers.
Sample type : tissue
Sample method: immunohistochemistry
Expression pattern : loss
Expression elevation: For all of the four markers detection, a nuclear immunoreaction was taken into account for evaluation. The lesions were considered as positive for each marker if tumor cells in the interest area showed immunoreactive intensity stronger than or equal to positive controls. The lesions were considered as negative for each marker if tumor cells showed complete loss of immunoreaction. Cases that at least one of four proteins was judged as negative were assigned to MMR-deficient cases and the remainder cases were assigned to MMR-retained cases.
Disease information
Related information
Funtion Uniprot: Heterodimerizes with PMS2 to form MutL alpha, a component of the post-replicative DNA mismatch repair system (MMR). DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages. Heterodimerizes with MLH3 to form MutL gamma which plays a role in meiosis.
UniProt ID: P40692
UniProt Link: https://www.uniprot.org/uniprotkb/P40692/entry
Molecular function from UniProt:
Tissue specificity from UniProt: Colon, lymphocytes, breast, lung, spleen, testis, prostate, thyroid, gall bladder and heart.
Subcellular UniProt: #Chromosome #Nucleus
Alternative name from UniProt:
Recommended name: DNA mismatch repair protein Mlh1
Gene name from HGNC: MLH1 (COCA2, FCC2, HNPCC, HNPCC2)
HPA class: Cancer-related genes Disease related genes Human disease related genes Plasma proteins
AlphaFold DB: P40692
AlphaFold Link: https://alphafold.ebi.ac.uk/entry/P40692
HPA link: https://www.proteinatlas.org/ENSG00000076242-MLH1
Tissue specificity RNA from HPA: Low tissue specificity
Tissue expression from HPA: General nuclear expression.
Single cell type specificity Low cell type specificity
Immune cell specificity: Low immune cell specificity
Subcellular summary HPA Located in Nucleoplasm
Cancer prognostic summary HPA Prognostic marker in liver cancer (unfavorable)
Pathology link: https://www.proteinatlas.org/ENSG00000076242-MLH1/pathology
Pathology endo: https://www.proteinatlas.org/ENSG00000076242-MLH1/pathology/endometrial+cancer
Survival figure legend: Kaplan-Meier survival curves of all cases according to mismatch repair (MMR) status. (
Survival curve link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302284/figure/F1/
Phenotype ID: 609310$158320 $ 276300$ 608089$ 619096$114500
Disease: Hereditary non-polyposis colorectal cancer 2 (HNPCC2) $ Mismatch repair cancer syndrome 1 (MMRCS1)$ Muir-Torre syndrome (MRTES) $Endometrial cancer (ENDMC) $Mismatch repair cancer syndrome 2 (MMRCS2) $Colorectal cancer (CRC) $
Note1: The disease is caused by variants affecting the gene represented in this entry $ The disease is caused by variants affecting the gene represented in this entry $The disease is caused by variants affecting the gene represented in this entry $Disease susceptibility is associated with variants affecting the gene represented in this entry $The disease is caused by variants affecting the gene represented in this entry $Disease susceptibility may be associated with variants affecting the gene represented in this entry
OMIM: 120436
OMIM link1: https://www.omim.org/entry/609310 $ https://www.omim.org/entry/276300 $ https://www.omim.org/entry/158320 $ $https://www.omim.org/entry/608089 $ $ https://www.omim.org/entry/114500
OMIM link2: https://www.omim.org/entry/120436
HGNC ID: HGNC:7127
HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7127